Skip to main content
    P

    Pliant Therapeutics Inc (PLRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.69
    -0.00 (-0.55%)

    Market Cap: $43.21M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Pliant Therapeutics Inc (PLRX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Pliant Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$149.34M, operating cash flow was -$128.34M and free cash flow was -$128.71M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$24.38M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $150.07M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$1.58M-83.7%100.0%-11654.7%-10211.1%
    Dec 2022$9.69M+27.9%100.0%-1313.4%-1273.3%
    Dec 2021$7.57M-81.9%100.0%-1288.1%-1284.5%
    Dec 2020$41.82M-26.7%100.0%-99.6%-99.3%
    Dec 2019$57.05MN/A100.0%-2.2%-1.1%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Revenue$0$0$1.58M$9.69M$7.57M$41.82M$57.05M$0N/A
    Cost of revenue$1.70M$0$0$0$0$0$0$666.00KN/A
    Gross profit-$1.70M$0$1.58M$9.69M$7.57M$41.82M$57.05M-$666.00KN/A
    Research and development$109.16M$169.31M$127.80M$96.94M$77.55M$66.19M$47.35M$24.41M$14.53M
    Operating income-$150.07M-$228.37M-$184.15M-$127.20M-$97.53M-$41.65M-$1.23M-$30.91M-$18.35M
    Net income-$149.34M-$210.30M-$161.34M-$123.32M-$97.26M-$41.53M-$631.00K-$30.28M-$20.62M
    EBITDA-$145.09M-$223.73MN/A-$127.18M-$94.74M-$40.34M-$118.00K-$30.25M-$18.06M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$2.27M$0$0$0$4.84M
    Gross profit$0$0$0-$365.00K$0$0$0$1.14M$0$0$0$4.38M
    Operating income-$25.74M-$23.86M-$21.77M-$23.58M-$28.27M-$45.59M-$58.94M-$53.32M-$62.01M-$60.64M-$52.39M-$47.04M
    Net income-$24.38M-$22.37M-$20.04M-$23.58M-$26.30M-$43.30M-$56.17M-$49.73M-$57.76M-$55.85M-$46.95M-$41.11M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $1.45M by $44.00M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$225.23M$396.95M$512.15M$350.61M$221.22M$295.53M$119.06M$66.53M$6.55M
    Current assets$196.45M$362.26M$505.50M$340.31M$209.44M$290.75M$111.90M$61.73M$4.71M
    Cash and equivalents$45.45M$71.19M$63.23M$33.69M$51.66M$50.88M$85.81M$60.95M$4.25M
    Total liabilities$44.02M$92.87M$38.58M$37.27M$22.16M$12.46M$9.08M$67.41M$3.19M
    Short-term debt$1.45M$542.00K$1.32M$2.46M$1.87MN/AN/AN/AN/A
    Long-term debt$0$30.21M$10.05M$9.93M$0N/AN/AN/AN/A
    Shareholder equity$181.21M$304.08M$473.58M$313.34M$199.06M$283.06M-$76.30M-$882.00K$3.35M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$169.88M$189.88M$202.60M$225.23M$276.60M$299.82M$344.77M$396.95M$445.67M$483.73M$521.61M$512.15M
    Total liabilities$43.24M$42.95M$37.43M$44.02M$76.29M$79.74M$87.61M$92.87M$99.84M$91.05M$84.27M$38.58M
    Cash and equivalents$26.57M$24.88M$22.19M$45.45M$93.73M$86.82M$91.94M$71.19M$79.62M$80.39M$114.30M$63.23M
    Shareholder equity$126.63M$146.93M$165.17M$181.21M$200.31M$220.08M$257.16M$304.08M$345.82M$392.68M$437.33M$473.58M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$128.34M-$155.50M-$116.36M-$94.63M-$75.44M-$37.27M-$2.75M-$28.33M-$16.92M
    Capital expenditures$374.00K$3.85M$921.00K$1.76M$1.95M$1.53M$964.00K$2.32M$1.41M
    Free cash flow-$128.71M-$159.35M-$117.28M-$96.39M-$77.40M-$38.80M-$3.71M-$30.65M-$18.33M
    Share repurchasesN/AN/AN/AN/AN/A$0$2.58MN/AN/A
    Investing cash flow$134.29M$140.34M-$127.01M-$150.20M$73.70M-$210.87M-$17.93M-$2.32M-$1.41M
    Financing cash flow-$31.70M$23.12M$274.40M$226.85M$2.53M$213.21M$45.54M$87.35M$20.01M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$16.98M-$12.80M-$19.23M-$17.79M-$21.08M-$40.60M-$48.86M-$47.66M-$32.27M-$45.30M-$30.27M-$25.10M
    Capital expendituresN/AN/A$0$0$0$112.00K$262.00K$209.00K$896.00K$1.25M$1.49M$61.00K
    Free cash flowN/AN/A-$19.23M-$17.79M-$21.08M-$40.72M-$49.13M-$47.87M-$33.17M-$46.55M-$31.76M-$25.16M
    Last 12 quarters

    Frequently Asked Questions About PLRX

    What is Pliant Therapeutics' annual revenue?

    Pliant Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Pliant Therapeutics profitable?

    No. Pliant Therapeutics reported net income of -$149.34M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PLRX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$128.34M minus capital expenditures of $374.00K produced free cash flow of -$128.71M.

    How much debt does Pliant Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $1.45M and cash and equivalents of $45.45M.